CooperVision lens reduces progression of myopia

CooperVision 1-day soft contact lens reduced the rate of progression of juvenile-onset myopia

Adolescents who are myopic (nearsighted) typically have “progressive myopia”

 

Stockwinners offering sock research, wining stock and option picks since 1998

The British Contact Lens Association Clinical Conference ended on Sunday in Liverpool England. Among companies presenting at the conference were Cooper Companies.

Cooper Companies subsidiary CooperVision announced Saturday that “a pioneering contact lens therapy has considerable potential to impact the rising prevalence of myopia in children, according to highly-anticipated study outcomes presented today at the British Contact Lens Association Clinical Conference.”

At the conference, CooperVision reviewed three-year results from the clinical trial assessing a specially-designed, dual-focus myopia control 1-day soft contact lens in reducing the rate of progression of juvenile-onset myopia.

Adolescents who are myopic (nearsighted) typically have “progressive myopia” — that is, their nearsightedness becomes progressively greater over time. If left uncontrolled, myopia results in a higher incidence of complications such as retinal tears and detachments, glaucoma, cataracts, and a reduced quality of life.

Three-year findings indicated that use of the dual-focus contact lens was effective in slowing myopia progression 59% as measured by mean cycloplegic spherical equivalent and 52% as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision 1-day contact lens.

Three-year results indicated the dual focus lens was well accepted by children, and did not affect their daily activities. Children in both the test and control groups had a higher satisfaction with contact lenses over spectacles.

Parents of study participants also had a very positive response, noting their children could mostly manage their lens wear independently.

“No other prospective randomized controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a 1-day soft contact lens over three years,” the company remarked.

COO closed at $237.43. Shares have a 52-week trading range of $158.73 to $243.88.

To read stories similar to this, sign up for a free trial membership to Stockwinners; be sure to check the Market Radar section.

The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

 

 

Novo Nordisk reports data on Xultophy

stockwinners blog

The 77th Scientific Sessions of the American Diabetes Association is underway in San Diego, CA from June 9-13, 2017.

Xultophy 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight in adults with type 2 diabetes compared to treatment with basal-bolus therapy

stockwinners blog
The 77th Scientific Sessions of the American Diabetes Association is underway in San Diego, CA from June 9-13, 2017.


Novo Nordisk announced Saturday that new results from the phase 3b DUAL VII clinical trial showed that Xultophy 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight in adults with type 2 diabetes compared to treatment with basal-bolus therapy.

 

In DUAL VII, Xultophy 100/3.6 demonstrated non-inferiority in lowering A1C when compared to insulin glargine U100 in combination with insulin aspart.

 

The objective of non-inferiority trials is to compare a novel treatment to an active treatment with a view of demonstrating that it is not clinically worse with regards to a specified endpoint.

 

Those treated with #Xultophy 100/3.6 versus basal-bolus therapy also: Reached similar glycemic targets; demonstrated an 89% reduction in severe or blood glucose confirmed symptomatic hypoglycemic events and a 92% reduction for nocturnal severe or blood glucose confirmed symptomatic hypoglycemic events; experienced a weight reduction of 0.93 kg compared with a weight gain of 2.64 kg for people treated with the basal-bolus regimen; achieved glycemic control with no hypoglycemic episodes and no weight gain in the last 12 weeks.

 

A basal-bolus routine involves taking a longer acting form of insulin to keep blood glucose levels stable through periods of fasting and separate injections of shorter acting insulin to prevent rises in blood glucose levels resulting from meals.

 

Furthermore, patients treated with Xultophy 100/3.6 required a lower daily insulin dose compared with the basal-bolus treatment group — 40 units vs 84 units.

 

Adverse events were similar across both treatment groups. The safety profile of Xultophy 100/3.6 in DUAL VII was generally consistent with previous Xultophy 100/3.6 clinical trials.


NVO closed at $42.84. It has a 52-week trading range of $30.89 to $57.41.

 

To read stories similar to this, sign up for a free trial membership to Stockwinners; be sure to check the Market Radar section.

The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Barron’s is bullish on Chevron, Apple

Apple’s (AAPL) smart speaker is a “turning point” for personal technology

Comerica (CMA), SVB Financial (SIVB) and Zions Bancorp (ZION) are among banks that “should continue to benefit” from near-term rate hikes

Barron's Logo on stockwinners

Barron’s, the weekly publication owned by the Wall Street Journal, in its latest issue is bullish on several names. They include:

The unveil of Apple’s (AAPL) smart speaker is a “turning point” for personal technology and possibly for the company itself, Barron’s contends in a ‘Technology Trader’ column. The product and its array of “enticing” audio tech shows that Apple continues to innovate, the publication says, while cautioning that some observers see Apple’s arguably lackluster Siri digital assistant as a “giant hole” in the product as compared to competing offerings from Amazon (AMZN) and Alphabet (GOOG).

Shares of ATM-maker Diebold (DBD) could return 25%-40% over the next two years, Barron’s contends in a feature article. The company should lift EPS to at least $3 through 2020 as it realizes cost cuts and synergies from its acquisition of Wincor Nixdorf, the publication says. Additionally, while cash is sometimes called a declining medium amid the proliferation of online payment platforms, Diebold CEO Andy Mattes tells Barron’s that such pessimism is countered by the 5%-6% annual growth rate of paper notes in circulation.

Lam Research (LRCX) could gain 20% in a year, Barron’s contends in a feature article. The publication argues that as memory chip usage in cars, home appliances, and other machines increases — and China ramps its catch-up efforts in the space — investors should buy the industry’s “arms dealers;” that is, the companies that manufacture etching and lithography equipment. Barron’s names both Lam Research and Applied Materials (AMAT), but favors Lam Research.

Banks

Comerica (CMA), SVB Financial (SIVB) and Zions Bancorp (ZION) are among banks that “should continue to benefit” from near-term rate hikes, Barron’s contends in a feature article. The publication explains that most banks haven’t paid depositors more despite the start of rate hikes in late 2015, a trend which is expected to continue with the likely hike in June, which means higher profits for the banks. Small and mid-market names with significant depositor bases, good balance sheets, and many commercial customers will gain the most from the trend, Barron’s says, leading it to recommend the above-mentioned banks.

Energy Stocks

stockwinners.com/blog

Certain North American energy names “look attractive,” including Chevron (CVX), EOG Resources (EOG), Canadian Natural Resources (CNQ) and Noble Energy (NBL), Barron’s contends in a feature article. The sector “could be near a bottom” after dipping on the recent surprise gain in crude inventories, the publication adds.

Regeneron (REGN) appears expensive against short-term profit expectations, but the stock still looks good for growth investors given the company’s “long-term ability to generate more attempts at hit drugs than do peers,” Barron’s contends in a ‘Follow Up’ column.

To read stories similar to this, sign up for a free trial membership to Stockwinners; be sure to check the Market Radar section.

The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.